Clinical Trial

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Study acronym: CROWN
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment.
Protocol Amendment History 5 changes
minor Completion moved earlier: 2028-08-28 -> 2028-06-08 2026-07-30
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-23
notable Trial sites reduced: 89 -> 85 locations 2026-07-23
minor Completion pushed: 2028-07-19 -> 2028-08-18 2026-05-28
minor Completion pushed: 2028-06-19 -> 2028-07-19 2026-04-21
Trial Details
NCT Number NCT06694805
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 326 participants
Start Date 2024-12-02
Primary Completion 2026-08-19 (estimated)
Study Completion 2028-06-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-29